ARCA biopharma is a biopharmaceutical company focused on developing genetically-targeted therapies for cardiovascular diseases. Co.'s primary product candidate, Gencaro (bucindolol hydrochloride), is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that Co. is developing to treat cardiovascular disease, focusing on atrial fibrillation in patients with chronic heart failure. Co. also has pharmacogenetic and other patent rights to drug candidates that have potential indications in cardiovascular disease, oncology and other therapeutic areas. The ABIO stock yearly return is shown above.
The yearly return on the ABIO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ABIO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|